CAJ | 학술논문

目的：通过泰比培南酯对小鼠肺炎克雷伯菌感染模型药代动力学／药效学（ PK／PD）研究，预测最佳PK／PD参数。方法取临床肺炎克雷伯菌1株，用琼脂二倍稀释法检测泰比培南的最低抑菌浓度（ MIC）；构建小鼠的肺炎克雷伯菌肺部感染模型，给予3种剂量（50，15，3 mg? kg－1）的泰比培南酯，观察给药24 h后肺组织感染量变化，并用高效液相色谱（ HPLC ）法检测血药浓度。结果体外测得MIC为0．03μg? mL－1；在小鼠的肺炎克雷伯菌肺部感染模型中，3种剂量均对感染有治疗作用，PK／PD参数AUC／MIC、Cmax／MIC及T＞MIC的相关系数（r）分别为0．78，0．76和0．46。结论 AUC／MIC和Cmax／MIC参数是反映泰比培南酯对小鼠的肺炎克雷伯菌肺部感染疗效的主要PK／PD参数。
목적：통과태비배남지대소서폐염극뢰백균감염모형약대동역학／약효학（ PK／PD）연구，예측최가PK／PD삼수。방법취림상폐염극뢰백균1주，용경지이배희석법검측태비배남적최저억균농도（ MIC）；구건소서적폐염극뢰백균폐부감염모형，급여3충제량（50，15，3 mg? kg－1）적태비배남지，관찰급약24 h후폐조직감염량변화，병용고효액상색보（ HPLC ）법검측혈약농도。결과체외측득MIC위0．03μg? mL－1；재소서적폐염극뢰백균폐부감염모형중，3충제량균대감염유치료작용，PK／PD삼수AUC／MIC、Cmax／MIC급T＞MIC적상관계수（r）분별위0．78，0．76화0．46。결론 AUC／MIC화Cmax／MIC삼수시반영태비배남지대소서적폐염극뢰백균폐부감염료효적주요PK／PD삼수。
Objective To elucidate the pharmacokinetic/pharmacody-namic ( PK/PD ) parameters that predict tebipenem pivoxil efficacy against Klebsiella pneumoniae in murine lung infection model. Methods The minimal inhibitory concentration ( MIC ) of tebipenem pivoxil against Klebsiella pneumoniae was determined by standard two-fold agar dilution method.Three doses of 50, 15 and 3mg? kg-1 were given to lung infection models, respectively.The bacterial burden in lung was measured 24 hours after the initiation of treatment and the concentra-tion in plasma was determined by high performance liquid chromatogra-phy ( HPLC) .Results The MIC value was 0.03 μg? mL-1 .Three doses all showed effects on murine lung infection model.Three PK/PD parameters correlated with efficacy of tebipenem pivoxil were AUC/MIC ( r =0.78 ) , Cmax/MIC ( r =0.76 ) , and T >MIC ( r =0.46 ) . Conclusion PK/PD study indicates AUC/MIC and Cmax/MIC are PK/PD parameters, well correlated with the efficacy of tebipenem pivoxil against Klebsiella pneumoniae in murine lung infection model.